RA Needs Innovation
At least 1 in 20 people across the western world today are living with an immune-mediated inflammatory disease, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD).1
We at Gilead and Galapagos have forged a new partnership with complementary strengths, a passion for innovation, and a shared vision of transforming the treatment of inflammatory diseases.
We’re doing more and moving faster, together.
